{"id":"W4411073903","doi":"10.1016/j.kint.2025.05.006","title":"Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy","year":2025,"lang":"en","type":"article","venue":"Kidney International","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Novartis Pharma; Chinook Therapeutics; Novartis Pharmaceuticals Corporation; Novartis","keywords":"Medicine; Nephropathy; Clinical trial; Internal medicine; Intensive care medicine; Endocrinology; Diabetes mellitus","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001709167,0.0009039626,0.00123788,0.0002399617,0.0003152334,0.0006395388,0.0004776264,0.0008913535,0.004770296],"category_scores_gemma":[0.0007583289,0.0003160233,0.0008073824,0.000266596,0.0004639562,0.0005520483,0.0002718385,0.001783188,0.0005714399],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003597253,"about_ca_system_score_gemma":0.0007233974,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003306321,"about_ca_topic_score_gemma":0.001068181,"domain_scores_codex":[0.999564,0.0002299283,0.00003037105,0.00007511819,0.00004348751,0.00005711998],"domain_scores_gemma":[0.9995153,0.00008792169,0.0001232176,0.00003739548,0.00004783275,0.0001883979],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7135541,0.02821434,0.007531205,0.001574264,0.002247445,0.0003193252,0.0002899531,0.001009934,0.08024231,0.0002149855,0.003408768,0.1613933],"study_design_scores_gemma":[0.4824116,0.4705597,0.03092166,0.0000768206,0.001045497,0.0005502358,0.00007869607,0.0009776654,0.008154674,0.0002208054,0.004953615,0.00004897514],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903967,0.004564509,0.0007883357,0.000501401,0.0001205938,0.001020625,0.0006880296,0.0001548871,0.001764825],"genre_scores_gemma":[0.9919334,0.00215907,0.001345498,0.0007261767,0.0001539551,0.0007625755,0.001320356,0.00002572208,0.001573184],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004770296,"threshold_uncertainty_score":0.01595825,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01132799609236904,"score_gpt":0.3423714910776744,"score_spread":0.3310434949853053,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}